Due to the application of the modified retrospective approach during the first-time adoption of IFRS 9, Financial Instruments, and IFRS 15, Revenue from Contracts with Customers, as at January 1, 2018, all the following figures from comparative periods are shown unadjusted.
€ millions | See Note | 2018 | 2017 |
Sales | 44,404.4 | 44,009.5 | |
Cost of sales | -33,299.5 | -32,635.0 | |
Gross margin on sales | 11,104.9 | 11,374.5 | |
Research and development expenses1 | 7 | -4,280.2 | -3,103.7 |
Selling and logistics expenses | -2,494.3 | -2,430.2 | |
Administrative expenses | -1,149.0 | -1,144.3 | |
Other income1 | 8 | 1,803.4 | 584.5 |
Other expenses | 8 | -1,027.5 | -796.6 |
Income from equity-accounted investees | 10 | 69.6 | 76.8 |
Other income from investments | 10 | 0.8 | 0.5 |
EBIT | 4,027.7 | 4,561.5 | |
Interest income | 11 | 122.9 | 94.4 |
Interest expense | 11 | -276.2 | -281.5 |
Effects from currency translation | 11 | -30.4 | -138.8 |
Effects from changes in the fair value of derivative instruments, and other valuation effects | 11 | 5.9 | 40.2 |
Financial result | 11 | -177.8 | -285.7 |
Earnings before tax | 3,849.9 | 4,275.8 | |
Income tax expense | 12 | -891.6 | -1,227.5 |
Net income | 2,958.3 | 3,048.3 | |
Non-controlling interests | -61.0 | -63.7 | |
Net income attributable to the shareholders of the parent | 2,897.3 | 2,984.6 | |
Basic earnings per share in € | 36 | 14.49 | 14.92 |
Diluted earnings per share in € | 36 | 14.49 | 14.92 |